Register

Phase 3 Study of Dexpramipexole in ALS (EMPOWER)

First Published on Clinicaltrials.gov: 1/20/2011
Status: Ongoing, But Not Recruiting
ClinicalTrials.gov ID: NCT01281189
Sponsor: Biogen Idec
Purpose: The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
Phase: III
Treatment Type: Orally available in pill form
Trial Type: Double Blind Placebo Controlled
Estimated Enrollment: 804
Eligibility: 18 years to 80 years. Both genders. Not accepting healthy volunteers.
Details: Dexpramipexole oral tablet 150mg twice daily for up to 18 months ; Placebo oral tablet twice daily for up to 18 months.
Collaborator(s):
Location(s):
  • Little Rock, AR, 72201, United States
  • Phoenix, AZ, 85013, United States
  • Fresno, CA, 93701, United States
  • Orange, CA, 92868, United States
  • Sacramento, CA, 95817, United States
  • San Francisco, CA, 94115, United States
  • New Britain, CT, 06053, United States
  • Jacksonville, FL, 32224, United States
  • Miami, FL, 33136, United States
  • Tampa, FL, 33612, United States
  • Atlanta, GA, 30322, United States
  • Iowa City, IA, 52242, United States
  • Chicago, IL, 60611, United States
  • Indianapolis, IN, 46202, United States
  • Kansas City, KS, 66160, United States
  • Charlestown, MA, 02129, United States
  • Baltimore, MD, 21209, United States
  • Grand Rapids, MI, 49503, United States
  • Minneapolis, MN, 55404, United States
  • Rochester, MN, 55905, United States
  • Saint Louis, MO, 63110, United States
  • Charlotte, NC, 28207, United States
  • Durham, NC, 27705, United States
  • Winston-Salem, NC, 27157, United States
  • Lincoln, NE, 68506, United States
  • Lebabon, NH, 03756, United States
  • New York, NY, 10032, United States
  • Syracuse, NY, 13201, United States
  • Columbus, OH, 43210, United States
  • Cleveland, OH, 44106, United States
  • Portland, OR, 97213, United States
  • Hershey, PA, 17033, United States
  • Philadelphia, PA, 19104, United States
  • Pittsburgh, PA, 15213, United States
  • Nashville, TN, 37232, United States
  • Dallas, TX, 75214, United States
  • Houston, TX, 77030, United States
  • San Antonio, TX, 78229, United States
  • Salt Lake City, UT, 84132, United States
  • Charlottesville, VA, 22908, United States
  • Seattle, WA, 98195, United States
  • Randwick, Australia
  • Westmead, Australia
  • Herston, Australia
  • Melbourne, Australia
  • Gent, Belgium
  • Leuven, Belgium
  • Calgary, Canada
  • Montreal, Canada
  • London, Canada
  • Toronto, Canada
  • Vancouver, Canada
  • Lille, France
  • Limoges, France
  • Marseille, France
  • Montpellier, France
  • Nice, France
  • Paris, France
  • Berlin, Germany
  • Bochum, Germany
  • Hannover, Germany
  • Jena, Germany
  • Ulm, Germany
  • Dublin, Ireland
  • Amsterdam, Netherlands
  • Nijmegen, Netherlands
  • Utrecht, Netherlands
  • Barcelona, Spain
  • Madrid, Spain
  • Goteborg, Sweden
  • Stockholm, Sweden
  • Birmingham, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
  • Newcastle, United Kingdom
  • Oxford, United Kingdom
  • Sheffield, United Kingdom
Primary Investigator:
Contact:
Trial Protocol as Published on Clinicaltrials.gov:
ClinicalTrials.gov
ALS Forum: View Forum Link